Highlights Aadi Bioscience, Inc.

Equities

AADI

US00032Q1040

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
1.86 ^USD	+6.29%		-2.11%	-7.92%

Mar. 13	Transcript : Aadi Bioscience, Inc., Q4 2023 Earnings Call, Mar 13, 2024
Mar. 13	Earnings Flash (AADI) AADI BIOSCIENCE Posts Q4 Revenue $6.3M	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (AADI) AADI BIOSCIENCE Posts Q4 Revenue $6.3M	Mar. 13	MT
Aadi Bioscience, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 13	CI
North American Morning Briefing : Stock Futures -2-	Mar. 13	DJ
Aadi Bioscience, Inc. Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations	Dec. 14	CI
Aadi Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Earnings Flash (AADI) AADI BIOSCIENCE Reports Q3 Revenue $6M	Nov. 08	MT
Aadi Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Earnings Flash (AADI) AADI BIOSCIENCE Reports Q2 Revenue $6.2M, vs. Street Est of $6.3M	23-08-09	MT
Earnings Flash (AADI) AADI BIOSCIENCE Reports Q1 Revenue $5.9M	23-05-10	MT
Aadi Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Aadi Bioscience, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-28	CI
Aadi Bioscience, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-28	CI
Earnings Flash (AADI) AADI BIOSCIENCE Posts Q4 Revenue $5.2M	23-03-28	MT
Aadi Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
Earnings Flash (AADI) AADI BIOSCIENCE Reports Q3 Revenue $4.2M	22-11-09	MT
Earnings Flash (AADI) AADI BIOSCIENCE Reports Q3 Revenue $4.2M	22-11-09	MT
Mirati Therapeutics, Aadi Bioscience Team Up to Study Lung Cancer Combination Treatment	22-10-12	MT
Aadi Bioscience, Inc. Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-Sirolimus at 34th EORTC-NCI-AACR Symposium	22-10-12	CI
Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with a KRAS[G12C] Mutation	22-10-12	CI
Aadi Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Aadi Bioscience, Inc.

Equities

AADI

US00032Q1040

Highlights

Filters